Ligand Pharmaceuticals LGND Accrued purchases of financial royalty assets
Accrued purchases of financial royalty assets at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid.
The official record: Ligand Pharmaceuticals’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's accrued purchases of financial royalty assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's accrued purchases of financial royalty assets?
- Ligand Pharmaceuticals (LGND) reported accrued purchases of financial royalty assets of $0 in Q4 2025.
- What does accrued purchases of financial royalty assets mean?
- Captures the value of acquired commercial license rights or royalty streams that have been committed to but not yet paid in cash. This metric reflects the company's ongoing investment in expanding its portfolio of royalty-generating assets. It serves as a leading indicator of future cash outflows required to settle contractual obligations for new intellectual property.